| Abstrakt: |
Background: Lamivudine and telbivudine are still the recommended treatment for hepatitis B, especially in Indonesia. However, no conclusive results on evaluation of the lamivudine and telbivudine therapy in Dr. Soetomo hospital in one-year therapy. Objective: To evaluate one-year Lamivudine and Telbivudine based on Hepatitis B Virus DNA, alanine aminotransferase, aspartat aminotransferase to platelet ratio index score, fibrosis-4, raid plasma reagin, platelet to lymphocite ratio score, transient elastography and liver biopsy. Methods: This is analytic observational study and carried out by evaluating secondary data from medical record in Dr. Soetomo hospital. results: Significant decreased of Hepatitis B Virus DNA, normalization of alanine aminotransferase, improvement of aspartat aminotransferase to platelet ratio index, PLR and Transient elastography in one year each of lamivudine (p = 0.00; p=0.00; p = 0.00; p = 0.00; p = 0.00) and telbivudine group (p = 0.00; p=0.00; p = 0.00; p = 0.00; p =0.00). In HbeAg negative and positive patients, there were no significant different between lamivudine and telbivudine based on Hepatitis B Virus DNA reduction, normalization of alanine aminotransferase, improvement of aspartat aminotransferase to platelet ratio index score, fibrosis-4, platelet ratio index, transient elastography and liver biopsy. However, there was significant difference between lamivudine and telbivudine based on raid plasma reagin score in HBeAg positive patient (p = 0.013). conclusion: There were no significant difference between lamivudine and telbivudine one-year therapy based on biochemical, virological, and fibrosis status in Dr. Soetomo hospital. [ABSTRACT FROM AUTHOR] |
